Market Pulse · Daily Scan
Daily Market Pulse
Jul 23, 2026 · sentiment/flow window ≈ 48h · Backdated run. Track A reflects the Thu 2026-07-23 regular-session close and the 48h window Tue 07-21 -> Thu 07-23, which captures the market's reaction to Alphabet/Tesla/IBM/ServiceNow earnings (all reported AMC 2026-07-22) plus a dense Thursday BMO earnings batch. Track B carries forward the 2026-07-22 run's 20 names per the project's own stability instruction, updating only GOOGL and TSLA where their own thesis-relevant catalysts realized inside this window.
Pre-marketnot publishedPost-market
TLDR;
A sharp, single-catalyst risk-off session: the S&P 500 fell 1.2%, the Dow 1.0%, and the Nasdaq 2.2% (its worst day in roughly a month), erasing Tuesday's semiconductor-led rally after Alphabet's ~$15-25B capex guidance raise (stock -7%) and Tesla's negative-free-cash-flow EPS miss (stock -14.5%) reignited 'AI ROI' anxiety, while IBM's mainframe-driven guidance cut (-2.2%) added further megacap-tech-specific pressure. ServiceNow's beat-and-raise (+5%) was a rare bright spot but did not offset the tape. This was compounded by a geopolitical/inflation shock: US-Iran tensions and Saudi-tanker strikes drove Brent/WTI up high-single-digits and pushed the 10-year Treasury yield to its highest level since January 2025 (~4.7%), while the VIX jumped into the high-teens (from mid-teens the day before). Breadth was decisively negative, with only energy and defense-adjacent names (LMT, RTX, Chevron) holding up against broad Communication Services/Consumer Discretionary/Tech weakness tied directly to the megacap earnings dispersion. Breadth: Narrow and negative - a single-name-dispersion selloff (GOOGL/TSLA/IBM) compounding an already-thinning advance/decline picture; only energy/defensive pockets (oil, defense primes) held up. Exact NYSE/Nasdaq A/D ratio for 07-23 specifically is UNVERIFIED; a prior-day (07-22) ratio of 1.26:1/1.86:1 (decliners:advancers) and a same-week technical note flagging 'cracks underneath the surface' in breadth corroborate the negative-breadth read..A · Daily Pulse
What moved — and why
▲ Rising — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | NOW | +5.3% | Beat-and-raise (subscription revenue guidance lifted) with the single richest options-implied move of the 07-22 AMC batch (~12.4%), yet the stock only realized about a third of that -- rallied to an intraday high near $101 before fading to close near $95.46. A genuine Street/retail split: Jefferies raised its target on a 98% renewal rate while retail sentiment trackers described the reaction as 'puzzled'. Included specifically because it is the one AMC name from 07-22 that beat AND rose, breaking the week's dominant 'beat-and-sold-off' pattern. | 71 |
| 2 | LMT | +10.7% | A $35B multiyear THAAD missile-defense award lifted backlog to a record $230.4B, layered on a Q2 beat and raised outlook -- one of the cleanest Tier-1 catalysts of the week. Low retail attention and an ambiguous single options print (almost certainly a hedge, not a signal) keep the options and sentiment subscores modest despite the size of the move. | 65 |
| 3 | URI | +10.2% | Record Q2 revenue with FY revenue/EBITDA guidance raised on infrastructure, power and industrial demand -- a clean beat-and-raise with no offsetting caveat, corroborating the power/electrification structural theme independently developed in Track B. | 64 |
| 4 | RTX | +7.8% | Q2 beat with 14% sales growth and guidance raised for the THIRD time this year -- missile-defense and commercial-aftermarket strength. Same defense-cycle-into-backlog theme as LMT and Track B's NOC thesis. | 60 |
| 5 | TMO | +8.71% | Q2 beat with 5% organic revenue growth and broad-based customer demand improvement. This is direct Tier-1 evidence for the 'life-science tools 2025 austerity consensus was wrong' thread flagged independently in the 07-22 Track B research (Thermo Fisher was cited there accelerating to +10.49% growth) -- ILMN's Track B downside thesis explicitly names this as the risk that could break it. | 59 |
| 6 | DGX | +8.61% | Q2 beat with total requisition volume up 13.1% on testing-partnership growth -- a second, independent confirmation (alongside TMO) that the life-science/diagnostics 'demand is soft' narrative from 2025 was overstated. | 56 |
| 7 | CSX | +6% | Q2 revenue beat with +10% revenue growth on freight-volume and fuel-surcharge gains, plus raised outlook. Corroborates the 'freight is recovering, not recessing' consensus-prior-check flagged in the 07-22 Track B research (Cass truckload linehaul +5.6% YoY). | 55 |
| 8 | HON | +4.71% | Q2 earnings plus a new IndiGo aerospace deal disclosed the same day -- a combination catalyst (earnings plus a discrete commercial win) rather than pure guidance momentum. | 52 |
| 9 | NSC | +5.32% | Adjusted EPS beat $3.32 consensus on volume and fuel-surcharge gains -- a second rail name (with CSX and UNP) confirming freight-volume recovery the same session. | 52 |
| 10 | UNP | +4.3% | Q2 beat by $0.22 with domestic intermodal shipments up 19%, plus continued merger-momentum commentary around the pending Norfolk Southern combination. Third rail name confirming freight recovery. | 51 |
▼ Falling — dailycomposite
| # | Ticker | Move | Driver | Score |
|---|---|---|---|---|
| 1 | TSLA | −14.5% | Q2 EPS $0.33 missed the ~$0.49-0.51 consensus by roughly 35-38% despite a revenue beat and 25% delivery growth; operating income -57% YoY, negative free cash flow, capex +142% YoY. Options had priced roughly a 6% move; the realized move was more than double that -- one of the cleanest realized-vs-implied misses of the week. This is the Track A instance of the Track B downside thesis (rank 3) actually landing: the stock did precisely what that thesis described. | 94 |
| 2 | GOOGL | −7.13% | Revenue beat (+24%, Cloud +82%) but the FY26 capex guide raised to $195-205B (from $180-190B) is what the market repriced. This is the Track A instance of the Track B upside thesis (rank 2) taking its first real test -- the 07-22 Track B write-up explicitly named this exact capex-guide reaction as 'what creates the entry rather than invalidating the thesis.' Notable divergence: retail sentiment trackers stayed net-bullish through the drop, unlike TSLA where sentiment flipped negative. | 83 |
| 3 | STM | −15.3% | Strong Q2 (26% YoY revenue growth, EPS beat) but a Q3 revenue guide of ~$3.70B came in below the ~$3.79-3.80B consensus -- another 'beat, guided cautious, sold off' print. THE EXACT MAGNITUDE IS UNRECONCILED: sources range from a premarket -12% to a previously reported close of -18.67%; momentum subscore reflects the higher end with an explicit low-confidence flag rather than asserting a false-precision figure. | 65 |
| 4 | PLTR | −6.1% | No PLTR-specific catalyst -- collateral selloff riding the TSLA/GOOGL AI-capex reaction, plus recirculating insider-selling and valuation commentary and NHS-contract scrutiny (PLTR itself does not report until 08-03). Same pattern as the 07-22 run: crowded retail long de-risking on someone else's news. retail-heavyunverified | 62 |
| 5 | TMUS | −6.61% | Beat on profit but slower postpaid net-adds and a push to pricier plans raised churn/subscriber-growth concerns; revenue came in light. A subscriber-quality story, not a headline miss. | 54 |
| 6 | ROL | −9.27% | Residential lead-volume weakness with residential organic growth of only 3.6% -- a real demand-softening signal in a name usually treated as recession-resistant, worth flagging as a possible early consumer-health tell. | 53 |
| 7 | DOV | −7.8% | Refrigeration-segment consolidation costs and late deliveries pressured margins -- an execution issue, not a demand issue. | 51 |
| 8 | GL | −7.02% | Health-segment underwriting margin compression despite premium growth -- a margin story, not a top-line miss. | 50 |
| 9 | DECK | −6.09% | SG&A expenses rose and operating income declined despite sales growth -- a margin, not demand, story. | 49 |
| 10 | LUV | −6.19% | Fuel-expense pressure drove a reduced full-year adjusted EPS outlook -- a costs-not-demand story for a second consumer-adjacent name this session (with ROL). | 48 |
B · One-Year Conviction
Asymmetric 12-month skew
Free sources only. Valuation multiples and market caps are Tier-2 aggregator data (stockanalysis.com, sourcing S&P Global Market Intelligence / TipRanks) - NOT SEC-verified - and most quotes carry a 2026-07-24 to 2026-07-26 vintage, i.e. AFTER the nominal run date. Post-run-date PRICE REACTIONS were excluded from scoring. FY2027 consensus is paywalled for many tickers; where it was unavailable, 'estimate revisions' is inferred from price-target revision direction and current-year growth rather than from an observed estimate series, and the subscore is capped accordingly. True estimate-revision history (dollar revisions over time) is not available on any free source. TRACK B STABILITY NOTE: per the project's own instructions, Track B is a slow-moving signal and should not churn day to day; large day-to-day churn is itself a red flag. Accordingly this run CARRIES FORWARD the same 20 names, ranks and sub-scores from the 2026-07-22 run except where a name's own thesis-relevant catalyst was actually realized in this window (flagged per-entry below) -- this is the intended, correct behavior, not a shortcut.
▲ Upside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| TSM | The unavoidable chokepoint of the AI buildout and the cheapest way to own the cycle. Every other semiconductor name in this research - NVDA, AVGO, AMD, MRVL, CRDO, ALAB - is a TSMC customer, so it monetises the compute buildout regardless of whether merchant GPUs or custom ASICs win the architecture war. In a regime that has begun punishing capex spenders and de-rating high-multiple beneficiaries, TSM offers ~31% forward-year revenue growth at 19.05x forward earnings with $79.70B of net cash. Explicit forward-year consensus was obtainable here, which is rare in this dataset: 2026 revenue NT$5.38T (+41.4%), EPS NT$106.35 (+60.5%), 37 analysts; 2027 revenue NT$7.05T (+30.9%), EPS NT$136.05 (+27.9%). July PT raises: Barclays $625->$650 (07-16), TD Cowen $400->$440 (07-17). The persistent discount is geopolitical, not operational. | Taiwan geopolitical tail risk - unhedgeable, and the sole reason for the multiple discount; TSM bears the capex burden of the entire cycle (leading-edge plus CoWoS packaging), so a hyperscaler digestion phase hits its own capital intensity; reported 'TSMC stake sale' among June 2026 supply-chain worries - UNVERIFIED | 90 |
| GOOGL | The only megacap that is simultaneously the AI model layer, the distribution layer and the cloud layer, and the only one in this set with ACCELERATING revenue growth. The Q2 print released AMC on the run date itself delivered revenue $119.8B (+24%) with Cloud +82%; the prior quarter delivered EPS $5.11 against $2.63 consensus with Cloud +63% on a $460B backlog. 2026E revenue $489.12B (+21.4%), accelerating from +15.1% in 2025; 2026E EPS $14.26 (+31.9%). Of 64 covering analysts, ZERO rate it Sell. The capex raise disclosed on the run date is precisely the regime change described above - the market repricing capex as cost - and that repricing is what creates the entry rather than invalidating the thesis. UPDATE (2026-07-23): the capex-driven drawdown described above as 'what creates the entry' has now happened -- GOOGL fell 6.9%-7.13% to ~$317.69 on 2026-07-23 despite the Q2 beat, precisely on the raised capex guide. Retail sentiment trackers notably stayed net-bullish through the drop (a genuine sentiment/price divergence versus TSLA, where sentiment flipped negative), and options positioning stayed net call-leaning post-print (P/C 0.48) rather than showing capitulation. The entry point is now measurably cheaper than at the 07-22 run date. | FY26 capex of $195-205B plus $811B of contracted future commitments materially compresses FCF - and the market has just demonstrated it will punish that; antitrust remedy overhang unresolved; search-query cannibalisation by AI assistants is a genuine long-term unknown that no current number resolves | 86 |
| NVDA | Carries the lowest forward multiple of any high-growth name in the AI complex (20.76x) while generating the highest free cash flow ($119.08B), having already de-rated relative to its growth while froth migrated into memory and optics. Its 52-week range ($164.07-$236.54) is the NARROWEST in the complex - roughly 44% peak-to-trough versus SNDK's reported +3,240% - meaning it is the least-crowded, most-owned-on-fundamentals name in a group where positioning is the primary risk. FY2027 consensus: revenue $393.6B, EPS $8.99, 53 analysts as of 07-22. The ~$500B NVIDIA-SK Group AI initiative locks down HBM supply - NVDA using its balance sheet to secure the one input that could constrain it. | ASIC substitution at the margin (Broadcom/Google TPU, Trainium) - the live architectural debate; hyperscaler concentration: any one of the big five cutting capex is the direct offset, and MSFT (07-29), AMZN and META are the swing events; China export restrictions remain an unquantified overhang | 84 |
| VST | The AI-power theme is fundamentally intact and broken on multiple, and that gap is the trade. Order evidence is stronger than at any point in the cycle (GE Vernova orders +88% YoY on a $176B backlog; Eaton Electrical backlog +29% with 1.1 book-to-bill; Quanta $48.5B backlog) while merchant IPPs sit 20-33% below their 52-week highs. The de-rating driver is the DISCOUNT RATE, not demand - and Vistra is where that dislocation is widest at 17.44x forward, 10.79x EV/EBITDA and a PEG of 0.38. All six Jun-Jul analyst actions maintained Buy; Wells Fargo moved its target $152 -> $259 on 07-03. FY2026E revenue $23.28B (+31.23%), EPS $8.45 (+77.55%). ERCOT + PJM merchant nuclear/gas fleet with direct hyperscaler exposure, plus the June 2026 KKR/Nvidia/Vistra 'Helix Digital Infrastructure' $10B venture. Backdrop: Morgan Stanley models US data-centre power demand at 74 GW by 2028 against ~25 GW available today. | D/E 3.55 and $19.93B of debt into a probable September hike - the most rate-exposed name on this list; merchant power spreads are unhedged commodity exposure, so a mild weather year is an earnings miss; the source statistics page is cached 2026-05-29 - multiples are approximate | 83 |
| MSFT | A SELLER of the agentic tools disrupting the rest of software, trading at the cheapest forward multiple in years (20.61x) and ~31% below its high with estimates still accelerating. Azure + Copilot + the OpenAI stake is the widest moat in software, and unlike app-layer SaaS it sits on the correct side of the seat-pricing question. FY26E revenue $329.55B (+17.0%), accelerating from +14.9%; FY26E EPS $16.77 (+23.0%). 42 Strong Buy / 13 Buy / 3 Hold of 58. ↔ deep-dive | the 07-29 capex guide is the sector's key swing factor - MSFT is NOT exempt from the capex-as-cost repricing that hit Alphabet, and it lands INSIDE the catalyst horizon of this run; sources conflict materially on MSFT's own 2026 capex - $120B+ (Futurum, Forbes) vs ~$190B (Tier-3 aggregator) - UNVERIFIED; Copilot seat monetisation is the same seat model being questioned elsewhere | 82 |
| AZN | The only large-cap pharma compounding EPS at a double-digit rate THROUGH its own IRA repricing, without needing an obesity story or a patent cliff to defend. Farxiga was in IRA Round 1 with negotiated prices effective 2026-01-01 - and AZN is still guiding to ~12% EPS growth in both 2026 and 2027. Verified forward years: 2026 revenue $63.21B (+7.62%), EPS $10.25 (+11.94%); 2027 revenue $66.79B (+5.66%), EPS $11.51 (+12.25%). JPMorgan moved $165 -> $213 on 2026-07-21 - a 29% target increase one day before the run date. Consensus PT implies the widest upside of any large-cap pharma in this research. | drug-pricing policy is now a REALISED earnings event rather than an overhang - which cuts both ways; extreme target dispersion: Deutsche $153 vs Jefferies $233, a 52% bull/bear gap; HSBC downgraded at $183 (07-13) and Morgan Stanley cut $220->$204 (07-16); ADR structure adds FX translation risk | 78 |
| MRK | Merck is pre-empting its own 2028 Keytruda cliff rather than waiting for it - systematically approving KEYTRUDA QLEX (subcutaneous) in lockstep with every new IV indication (TNBC 1L with Trodelvy 06-25; muscle-invasive bladder cancer with Padcev 07-10). Converting a franchise to a patent-protected subcutaneous formulation ahead of IV biosimilars is the entire LOE mitigation thesis, and it is executing on schedule. It separately opened a new market on 2026-07-16 when the FDA approved LIPFENDRA (enlicitide), the first and only once-daily ORAL PCSK9 inhibitor. READ THE VALUATION CAREFULLY: 2026 EPS consensus is $2.74 (-69.43%), a one-off charge year, versus 2027 EPS $9.66 (+251.83%) - roughly 13.6x 2027 earnings. Any screen ranking MRK on 2026 P/E produces a false signal. | +56% over 52 weeks against a consensus PT of $134.04 (+2.27%) - the re-rating has largely happened; the QLEX conversion rate is NOT disclosed - it is the single most important number for this thesis and it is UNVERIFIED; $43.4B net debt; MK-1167 Alzheimer's Phase 2 terminated ~07-19; source data conflict: quote page shows PT $131.70 vs forecast page $134.04, unreconciled | 78 |
| LLY | The single most important structural fact in mid-2026 healthcare is that US GLP-1 NET PRICING has collapsed by government design while VOLUME has been unlocked - a volume-for-price trade. TrumpRx (Tier 1, US government) now sells Zepbound at $299/mo from a $1,087 list, and Medicare covers obesity drugs for the first time at a ~$50/mo copay. That asymmetry rewards whoever takes enough share to more than offset price. Lilly is the only company owning BOTH the injectable incumbent (Zepbound/Mounjaro) AND the oral disruptor (Foundayo/orforglipron, FDA-approved 2026-04-01), with retatrutide behind it - and the TRIUMPH Phase 3 read out on 2026-07-23 at up to -20.8% body weight. MFN price compression transfers share TO Lilly rather than away from it. 2026 revenue $85.35B (+30.95%), EPS $34.62 (+43.01%); 2027 revenue $98.74B (+15.69%), EPS $44.87 (+29.59%). July PT raises: Citi $1,500->$1,600, Bernstein $1,300->$1,385, UBS $1,250->$1,425. | at 33.5x forward with a consensus PT implying only ~+6%, the sell side sees the story as fully priced - the weakest valuation support of any name on this upside list; MFN/TrumpRx is structurally deflationary even for the winner; Novo sued Lilly on 2026-07-21 and sought a preliminary injunction on 07-24 to block Lilly's DTC advertising - a live legal risk to its key launch channel | 78 |
| AEM | Essentially unlevered equity on the gold price, with the best margin structure and balance sheet in this research. Gold at ~$4,124 on the run date (+21.4% YoY) against a largely fixed cost base is direct margin expansion - and unlike oil, gold's drivers here (geopolitical instability PLUS an inflationary oil shock) are reinforced rather than undermined by the Iran situation. D/E of 0.01 means shareholders capture the full operating leverage with essentially no financial risk: 39.46% profit margin, 7.31x EV/EBITDA, 11.62x forward earnings, $4.54B TTM FCF, total debt $319M against $3.12B cash. Hold ratings fell 6 -> 4 over six months. | a durable US-Iran settlement removes the geopolitical bid - reports of Pakistan/China mediation already knocked crude ~3% on 07-24; a September rate hike raises real yields, gold's primary headwind; FY27 EPS growth decelerates sharply to +5.67% - the easy comps end, and the analyst PT range ($87-$300) is extraordinarily wide, signalling low conviction on the gold deck | 76 |
| NOC | The defense cycle is intact and the trade has inverted: money moved out of narrative (PLTR -20.5%, TDG -22.6%, AXON -28.8%, LDOS -31.6%, AVAV -45.2% over 52 weeks) and into appropriated backlog (HWM +55.2%, LMT +38.9%, RTX +36.0%, GD +22.0%). NOC is the ONLY large prime down over 52 weeks (-4.62%) - and it beat and raised on 07-21, one day before the run date: EPS $7.68 vs $6.82, FY26 EPS guidance raised to $28.60-29.10 from $27.40-27.90, a record $105B backlog and $20B of net awards (~1.9x quarterly book-to-bill). The FY2027 budget request (released 2026-04-03) is $1.5T total defense, +24% real discretionary, weighted to hardware, with ~$55B for a Defense Autonomous Warfare Group where NOC has the deepest franchise among primes. EV/EBITDA has compressed from 21.38 in FY2023 to 14.92. | THE UNRESOLVED QUESTION: six firms cut price targets IMMEDIATELY AFTER the beat-and-raise (Susquehanna $785->$655, Baird $700->$500, DB $645->$615, JPM $635->$600, TD Cowen $580->$550), and only UBS raised. B-21 initial LRIP lots are fixed-price - historically NOC's charge mechanism - and current charge status is UNVERIFIED. This is the single most important unresolved item in the defense work and the reason the estimate-revisions subscore is capped at 68.; Sentinel ICBM cost/schedule breach risk; the FY27 budget is a REQUEST, not law - discretionary spending needs 60 Senate votes | 74 |
▼ Downside skew — 1yrconviction
| Ticker | Thesis | Key risk | Score |
|---|---|---|---|
| ARM | Grows revenue ~21-23% and trades at ~120x forward earnings - a PEG above 5 - with EV/EBITDA at 238.99. The structural problem the AI cycle does not fix: royalty revenue scales with UNITS, not with silicon value, and units are falling (smartphones -12.9%, PCs -11.3%, per IDC). This is the clearest negative revision cluster in the semiconductor complex: HSBC downgraded to Hold from Buy on 2026-07-14 citing foundry capacity constraints limiting earnings growth; UBS cut $470->$360 on 07-20 (-23%); Wells Fargo cut $410->$350 on 07-22, the run date itself (-15%). Only Susquehanna raised. FY2027 consensus: revenue $5.97B (+21.3%), EPS $2.17 (+22.5%), 37 analysts. | datacentre CPU attach (Grace/Graviton/Axion) could inflect royalty RATES rather than units; any AI-licensing announcement re-rates it instantly; SoftBank ownership concentration makes the float squeezable - this is the real hazard in shorting it; earnings 2026-07-29, INSIDE the catalyst horizon | 81 |
| NVO | Triple structural price compression on the same molecule, all three confirmed. (a) TrumpRx MFN pricing: Ozempic $199/mo from $1,028, Wegovy Pen $199 from $1,349 (Tier 1, trumprx.gov). (b) IRA Round 2: Ozempic AND Wegovy negotiated at -44% net, effective 2027-01-01 - i.e. INSIDE the 12-month window. (c) Competitive share loss: Lilly's orforglipron launched 2026-04-01 and retatrutide read out 2026-07-23. Novo eats the price cut without the offsetting share. The tell is mechanical: forward P/E (16.00) is HIGHER than trailing (11.48) - the market is explicitly modelling earnings decline. 2026 consensus revenue DKK 293.81B (-4.94%), EPS 20.97 (-8.93%), 28 analysts, and the consensus PT sits BELOW the market price. Guidance was cut 2026-02-04 citing pricing pressure, patent expirations and competition; CagriSema missed and requires a new study. Behavioural tell: Novo sued Lilly on 2026-07-21 and sought a preliminary injunction on 07-24 to block a competitor's advertising - not the posture of a company winning on product. | semaglutide has real volume upside from Medicare's first-ever obesity coverage at a ~$50/mo copay; 9.1x EV/EBITDA on a 37.2% net margin is genuinely cheap - this is a crowded, already-repriced short; HSBC raised its target to DKK 300 on 07-21; Q2 earnings 2026-08-05, same day as LLY | 79 |
| TSLA | Volumes are recovering while economics collapse. The Q2 print released AMC on the run date itself: revenue $28.236B BEAT consensus $26.4B and deliveries grew 25% YoY to 480,126 - but non-GAAP EPS was $0.33 against ~$0.51 consensus, operating margin 1.4%, operating income -57% to $398M, and free cash flow -$1.092B with capex +142% to $5.8B. Tesla has converted from an auto manufacturer earning 15%+ operating margins into a capex-heavy AI/robotics R&D vehicle funded by a barely-profitable car business. At ~162x forward earnings with negative FCF, essentially the entire market cap is the robotaxi/Optimus option - and management offered limited new concrete milestones on either on the call. UPDATE (2026-07-23): the thesis has now materialized almost exactly as described -- Q2 non-GAAP EPS $0.33 missed the ~$0.49-0.51 consensus by roughly 35-38%, and the stock fell 14.4%-14.5% to ~$319.69, a realized move roughly 2.4x-2.5x what options had priced pre-print (~6%). UBS cut its price target to $385 on the print; at least five other analysts cut targets the same day. Because so much of the bear case is now realized in the price, the fundamental-valuation subscore is trimmed slightly to reflect a less attractive NEW entry for a short, even though the structural critique (capex-funded, barely-profitable core business) is unchanged and, if anything, confirmed. | a credible, dated, revenue-generating robotaxi rollout at scale - the option is real, not fictional; deliveries are GROWING 25%, not shrinking: the post-credit-expiry demand cliff bears expected did not materialise; net cash of ~$27B means no financing risk and no forced-deleveraging catalyst - this can stay expensive indefinitely; data conflict: Q2 deliveries reported as 480,126 (Electrek) vs 489,126 (Teslarati), unreconciled | 76 |
| QCOM | The ONLY large cap in the entire semiconductor universe screened with declining consensus revenue AND declining EPS. FY2026 consensus: revenue $42.58B (-3.86% YoY), EPS $10.81 (-10.14% YoY), 31 analysts. Three independent structural pressures compound at once: losing its largest socket to Apple modem in-sourcing, paying more for inputs (memory crunch - it signed long-term automotive memory supply agreements with Micron ~07-17, which is sensible AND confirms where the pricing power sits), and selling into a shrinking unit market (smartphone units -12.9%, IDC). UBS cut $235->$190 around 07-21. INFERENCE, FLAGGED AS MINE: a 16.94 forward P/E at $166.97 implies forward-year EPS of ~$9.86 - BELOW the FY2026 estimate of $10.81 - meaning consensus appears to model two consecutive down years. This is my arithmetic from the aggregator's own figures; the FY2027 consensus itself was paywalled. | 16.9x with $12.5B of FCF and ~32% consensus upside is not an expensive short; auto/IoT diversification is real and growing; already ~36% below its 52-week high, so much of the modem cliff is priced; FQ3 earnings 2026-07-29, INSIDE the catalyst horizon | 76 |
| MRNA | The cleanest negative asymmetry in this research on the numbers. The stock is +87.5% over 52 weeks while revenue FELL 30% to $2.23B TTM, gross margin is NEGATIVE (-69.9%), operating margin is -113.9%, TTM FCF is -$1.60B and EPS is -$8.16. Consensus PT of $45.85 sits ~44% BELOW spot, rated Hold by 24 analysts. Equity eroded from $13.85B to $7.41B while debt went from ~zero to $1.25B. Management reorganised into three franchises explicitly preparing for launches in 2027 and 2028 - the company itself does not expect 2026 to be the revenue trough. RUNWAY (my arithmetic from two sourced figures, flagged as inference): net cash ~$3.96B against -$1.60B annual FCF implies roughly 2-2.5 years; company runway guidance is UNVERIFIED. | A NEAR-TERM BINARY SITS DIRECTLY ON TOP OF THE RUN-UP: the mRNA-1010 flu vaccine PDUFA is 2026-08-05 and the adcomm voted 9-0 in favour on 2026-06-18. An approval is a real, dated, high-probability-looking catalyst against this short.; Merck-partnered intismeran autogene cut melanoma recurrence/death risk 49% at 5 years (2026-06-01); Q2 earnings 2026-07-31 | 76 |
| DE | A peak-quality multiple on trough-and-still-falling fundamentals: 31.65x forward earnings on a third consecutive year of revenue decline. Revenue $61.25B (FY23) -> $51.72B (FY24) -> $45.68B (FY25); net income $10.17B -> $7.10B -> $5.03B; operating margin 25.26% -> 24.27% -> 20.64%. That is -25% revenue and -51% net income since FY2023. FY26E revenue $41.5B (-9.15%), FY26E EPS $18.06 (-2.36%). THE STRUCTURAL POINT IS TIER-1 AND UNDERAPPRECIATED: USDA ERS forecasts 2026 net farm income of $153.4B (-2.6% inflation-adjusted), and the support is TRANSFER PAYMENTS, not demand - government payments +45.2% to $44.3B, 'primarily due to higher anticipated payments from Farm Bill programs that trigger payments when commodity prices fall', while crop cash receipts rise only +1.2% (a decline in real terms). Farmers receiving deficiency payments do not buy $800,000 combines; equipment capex tracks crop receipts, not total farm income. Quality-of-earnings flag: Q2 FY26 margins were partly boosted by a $272M one-time tariff refund. Citi raised its PT to $610 on 07-13 but kept Neutral - and $610 is BELOW the market price. | the trough-buying argument is live and has mainstream backing (Barron's, 2026-07-09: 'Farming Is Terrible Right Now. That's Good for Deere and AGCO Stocks'); the 2026-06-12 White House ag-equipment tariff cut is a direct cost tailwind; FY2027/28 estimates are being revised UPWARD, implying the street already treats FY2026 as the trough; precision-ag software and the dealer network are genuine moats | 73 |
| NET | The single most unsupportable large-cap multiple found in this research: ~202x forward earnings for 31.6% revenue growth, unprofitable (EPS -0.25), with the stock near its 52-week high AND a consensus price target of $259.84 that sits BELOW the current price. It is the only name in the entire cross-desk dataset where the sell side has marked its target under spot while the stock sits near its high - complete capitulation on upside with no valuation cushion. The broader structural point: the market spent 2026 punishing app-layer SaaS on terminal-value fear while data/infra/security names saw market caps rise 31-99% on 20-31% growth at 80-200x forward with GAAP losses. That cohort - NET, CRWD (140x fwd), SNOW (127x fwd), DDOG (100x fwd), PANW (82.5x fwd on EPS -34.1%) - is where the crowding, and therefore the unpriced downside, actually sits. In a probable-hike regime these are the highest-duration assets in software. | Cloudflare's edge/inference positioning is genuinely strategic and could see an AI-workload inflection that resets the growth rate upward; shorting momentum at a 52-week high is how people lose money; no debt distress; this is a MULTIPLE short, not a fundamental one - revenue is compounding at 31.6% | 72 |
| SLB | The cleanest structural short in energy because it loses in BOTH states of the world. The central paradox of mid-2026: crude is up ~38% YoY while SLB's earnings estimates are FALLING. Its book is international/offshore-weighted and concentrated in exactly the Middle East geographies now disrupted by the Iran conflict and Hormuz throttling - war raises the oil price but halts the drilling SLB is paid for (Saudi output already fell 7,010 -> 6,637 kbpd May->June 2026). Then, if the conflict resolves, prices fall toward EIA's $65 Brent 2027 case and operators cut budgets. FY2026 EPS $2.53, revised DOWN 13.73% from $2.93. FY2027 consensus assumes a +30.15% EPS rebound to $3.29 - an aggressive recovery resting on the same de-escalation that E&P bulls fear. THE TWO CONSENSUS VIEWS ARE MUTUALLY INCONSISTENT, and that inconsistency is the thesis. Corroborated intraday by Track A: HAL fell 5.47% on a double beat on 07-21 specifically on Middle East revenue -10.7%. | a durable peace could unleash pent-up Middle East reconstruction spend; FY27 consensus already assumes recovery, so a beat re-rates fast; consensus is still Buy with ~17% PT upside - this is a contrarian position; data flag: shown EV/EBITDA of 4.52 is irreconcilable with a 25.42 trailing P/E - flagged UNVERIFIED and not used; FCF listed as n/a | 72 |
| INFY | The purest expression of AI disrupting the labour-arbitrage pyramid, and one of very few names in software/services with genuinely FALLING forward estimates. Trailing P/E 13.17 vs forward P/E 13.26 - forward ABOVE trailing, the mechanical signal of negative revisions. Revenue TTM $20.30B, +4.1%: the weakest growth of any name examined across five research desks. Consensus rating Hold, only 14 analysts, PT implying ~+6.7% - by far the weakest analyst support in the dataset. The mechanism: services revenue is billable hours x headcount, precisely what agentic AI compresses. The sector repriced violently on 2026-06-18 when Accenture cut guidance from 3-5% to 3-4% local-currency growth, missed on revenue and posted bookings -2%; ACN fell ~18%, its worst single-day drop on record, with Capgemini -8.4%, CTSH -5.8%, INFY -3.2%. | THERE IS A REAL HOLE IN THE CONSENSUS STORY: Accenture's HEADCOUNT ROSE during the quarter it missed, CTSH's bookings rose 21%, and IBM tripled entry-level hiring despite claiming developers are 40% more productive. Revenue deceleration is documented; the causal attribution to AI is NOT.; at ~13x with ADR/FX effects, much is priced; if AI INTEGRATION demand materialises, services firms capture it; related names ACN (10.25x fwd, 4.44% yield) and CTSH (7.86x fwd, FCF +31.6%) are explicitly NOT recommended as shorts - too cheap; express as underweight | 70 |
| HWM | SHORT THE MULTIPLE, NOT THE BUSINESS - and the low composite reflects exactly that. The most extreme multiple expansion found anywhere in this research: forward P/E 24.29 (FY21) -> 26.72 (FY23) -> 36.19 (FY24) -> 48.99 (FY25) -> 54.80 now; EV/EBITDA 16.69 -> 45.56, a 173% expansion in five years; P/S 2.70 -> 13.42. A reversion to even the FY2025 EV/EBITDA of 36.35x is roughly a 20% drawdown with NO change to earnings. Consensus PT implies only ~+7.75% even at a Strong Buy rating. Q2 guidance ($2.39-2.41B revenue, $1.22-1.24 EPS, reporting 08-06) is a narrow band with little beat room. In a probable-hike regime, 45x EV/EBITDA is the most rate-sensitive kind of asset there is. | THIS IS NOT A FUNDAMENTAL SHORT AND THE ESTIMATE-REVISIONS SUBSCORE OF 40 SAYS SO EXPLICITLY: estimates are RISING. FY26E revenue $9.76B (+18.24%), EPS $5.06 (+34.31%); the company RAISED FY26 EPS guidance to $4.88-5.00 from $4.35-4.55; Jefferies, TD Cowen, Morgan Stanley, Citi and UBS all raised targets; consensus is Strong Buy.; genuine oligopoly in investment-cast turbine airfoils; the hyperscaler/industrial-gas-turbine demand leg is a new, uncorrelated vector the market may still be underwriting; 737 rate increases are direct volume | 60 |
C · Options Heat
Where the premium is paying up
| Ticker | Signal | Read | Implication | Lag |
|---|---|---|---|---|
| TSLA | iv_spike | pre-print ATM straddle implied ~5.76%-6% move (30-day IV ~49-50%, IV rank ~37.9); REALIZED move -14.5% was roughly 2.4x-2.5x what was priced. Post-print call volume 770,000 (~2x avg), put volume 695,000 (~2x avg); most-active contract was the weekly 7/24 $330 put with new opening put buying. | bearish, realized after the fact. Realized vol had been running above implied for weeks pre-event, per the source's own analysis - a flagged warning sign that the options market had not caught up to the deteriorating setup. | Schaeffer's/options-blog derived; day volume not vol-vs-prior-OI; no consolidated sweep tape. |
| GOOGL | iv_spike | pre-print short-dated IV ~60% (vs a normal 24-35%) implied ~5.4%-7.09% move; realized -7.13% landed at/beyond the top of the priced range. Post-print P/C moved to 0.48 (put volume 93,832 vs call volume 194,605) - increased put buying but still net call-leaning. | uncertain/reassessment, not capitulation - the chain stayed call-heavy even as the stock fell, consistent with the Track B thesis that a structural long survived a valuation repricing. | Options-blog derived (Options Trading Report, TipRanks); no raw exchange chain data. |
| IBM | iv_spike | pre-print implied move ~6.87%-7% (TipRanks); realized reaction was a muted +2% -- realized well inside the implied range, consistent with a meaningful post-print IV crush | bullish/neutral - the market had priced a much larger move than materialized | TipRanks options-tool snapshot; no post-print IV reading captured to confirm the crush magnitude numerically. |
| NOW | iv_spike | pre-print implied move ±12.41%-12.66% (TipRanks) - the richest event premium of the 07-22 AMC batch; realized move only ~5%, well inside what was priced | uncertain - large event premium not fully monetized in either direction; IV crush is the dominant post-event exposure for anyone who bought the straddle | TipRanks-derived; no post-print IV reading captured. |
| TXN | iv_spike | pre-print implied move ±9.31% (TipRanks, 07-22 AMC report); realized -3.13% on 07-23 landed well inside the priced range | uncertain - 'sell the news' on an upbeat forecast; the size of the move undershot what options had priced | TipRanks-derived; no post-print confirmation gathered. |
| LMT | sweep | a single Benzinga-flagged 9/18-exp $570 put, 401 contracts, tagged 'bearish', printed 3:55pm on 07-23 -- the same afternoon the stock closed +10.5-11% | most likely a protective hedge on a large winning position rather than a genuine bearish bet; flagged as a data-quality caveat on automated options-sentiment tagging, not a directional signal | Single free-tier print, no OI or opening/closing context available. |
| CBOE_EQUITY_PC | pc_skew | STILL UNRESOLVED, DO NOT QUOTE A LEVEL. Convex's series shows 07-21 1.25, 07-22 1.60, 07-23 1.95 (a further step up); CBOE.com's own live snapshot (fetched 2026-07-26) shows Total P/C 0.99, Equity P/C 0.79 -- roughly half the Convex reading. YCharts' CBOE Equity Put/Call Ratio series has no data past 2026-07-10. | No name-level or market-level P/C conclusion is drawn. The one directional note offered without an absolute level: the Convex series rose through the window (1.25->1.60->1.95), consistent with the market paying up for downside protection into the selloff -- but the series itself may be mislabeled or differently constructed, so this is offered as color, not a number. | Two free sources disagree by roughly 2x on the same nominal series and neither has a verified historical archive covering this exact date. |
| VIX_COMPLEX | iv_spike | VIX closed in the 18.7-19.2 range on 07-23 (up sharply from 16.64 on 07-22), then eased to 18.58 by 07-24 close. A separate SKEW read from 07-22 (151.66, +3.8%) showed elevated OTM downside-put pricing already building INTO this session. | A real, if orderly, vol event -- the market paid up for protection into the print and the realized move (especially TSLA) justified it. Not a panic spike: VIX stayed in the high-teens, not the 25+ range associated with disorderly selloffs. | VIX close figure for 07-23 has two independent Tier-2 sources in the 18.7-19.2 range; a third source's 16.64 figure is rejected as a same-number-as-prior-day artifact. |
D · Catalyst Calendar
Upcoming events
| Date | Event | Tickers | IV move |
|---|---|---|---|
| 2026-07-24 | Q2 2026 earnings (BMO) - broad cross-sector day | VZAXPCHTRSLBHCANEECNILWBAH | unknown |
| 2026-07-27 | Q2 2026 earnings (BMO) - Track B upside rank varies by run; first live test of the ~12% EPS growth guide | AZN | unknown |
| 2026-07-27 | Durable Goods Orders (June), 08:30 ET; Dallas Fed Manufacturing; $69B 2-yr and $70B 5-yr Treasury auctions | MACRO | normal |
| 2026-07-27 | Q2 2026 earnings - day placement per a single aggregator, UNVERIFIED | BKRNUEAPLDWHR | unknown |
| 2026-07-28 | Q2 2026 earnings; KO BMO 08:30 ET call confirmed via Coca-Cola IR | BAVUPSPYPLKOFSTXENPHRCLKLAC | unknown |
| 2026-07-28 | Advance Goods Trade Balance; Case-Shiller 20-City Home Price Index (May); Richmond Fed Manufacturing + Conference Board Consumer Confidence (July); $44B 7-yr Treasury auction | MACRO | normal |
| 2026-07-29 | FOMC INTEREST RATE DECISION 14:00 ET + Fed Chair Kevin Warsh press conference 14:30 ET. Tier-1 confirmed via federalreserve.gov. | MACRO | high |
| 2026-07-29 | FY26 Q4 earnings (AMC) | MSFT | high |
| 2026-07-29 | Q2 2026 earnings (AMC) | META | high |
| 2026-07-29 | Q2/FQ3 2026 earnings | QCOMARMPGSBUXBSXADP | unknown |
| 2026-07-30 | FQ3 2026 earnings (AMC) | AAPL | normal |
| 2026-07-30 | Q2 2026 earnings (AMC) | AMZN | high |
| 2026-07-30 | Q2 GDP advance estimate, Personal Income/Spending + PCE and Core PCE Price Index, weekly jobless claims - all 08:30 ET, the day after the FOMC decision | MACRO | high |
E · Trade Ideas
What the data implies
TSLAneutral · track A/B
Rationale Q2 EPS $0.33 missed ~$0.49-0.51 consensus by ~35-38%; options had priced only a ~6% move and the stock realized ~14.5% -- a clean realized-vs-implied miss. This is the Track B downside thesis (rank 3) landing in real time. But UBS and five other analysts already cut targets the same day, meaning much of the bad news is now in both the price and the sell side's own numbers.
Invalidation a credible, dated, revenue-generating robotaxi rollout at scale, or deliveries decelerating from the current +25% pace would each independently break either side of this
Risk net cash of ~$27B removes financing risk as a forced catalyst in either direction; this is a valuation argument, not a solvency one.
GOOGLlong · track A/B
Rationale Revenue beat (+24%, Cloud +82%) but the market repriced the FY26 capex guide ($195-205B) with a 7.13% drawdown. Retail sentiment stayed net-bullish through the drop and options positioning stayed call-leaning post-print -- neither shows capitulation. This is the Track B upside thesis (rank 2) taking its first live test; the drawdown is what the 07-22 write-up explicitly called the entry, not the exit.
Invalidation a capex guide that keeps rising without Cloud backlog growing to match, or FCF compression showing up in a subsequent quarter with no offsetting Cloud acceleration
Risk antitrust remedy overhang and AI-driven search cannibalization remain unresolved and are NOT addressed by this print either way.
NOWneutral · track A
Rationale The single richest options-implied move of the 07-22 AMC batch (~12.4%) on a genuine beat-and-raise, yet the stock realized only about a third of that priced move and closed well off its intraday high. A real Street/retail split: Jefferies raised its target on a 98% renewal rate while retail sentiment trackers described the reaction as 'puzzled'.
Invalidation n/a for the vol view; directionally, a close back below the pre-earnings level would negate the 'this is different from TSLA/GOOGL' read
Risk the stock remains reported ~30% below its 200-day EMA per one source, a longer-run technical headwind independent of this quarter's result.
LMTneutral · track A
Rationale A $35B THAAD award lifted backlog to a record $230.4B alongside a beat-and-raise -- the cleanest Tier-1 catalyst of the session. A single automated options print tagged 'bearish' on the same up day is almost certainly a hedge on an existing winning position, not a signal; flagged as a data-quality caveat rather than acted upon.
Invalidation a formal cancellation or rescoping of the THAAD award, or evidence the guidance raise was one-time/tax-driven rather than backlog-driven
Risk defense-budget items remain requests, not enacted law, until Congress passes appropriations.
STMshort · track A
Rationale Strong Q2 (26% YoY revenue growth, EPS beat) undercut by Q3 guidance below consensus -- the same 'beat, guide cautious, sell off' pattern as several other names this earnings season (TEL, DHR, NOC on 07-22). The magnitude of the move is itself unreconciled across sources (-12% to -18.67%), which argues for a defined-risk expression given genuine uncertainty about how much is already priced.
Invalidation Q3 guidance being reaffirmed or exceeded at the next print would directly contradict the cautious signal
Risk ADR structure adds FX considerations; free-tier options coverage on this name is thin.
Methodology & limitations
- BACKDATED RUN, compiled 2026-07-26 for a 2026-07-23 run date. Track A moves/closes/catalysts are strictly in-window; the market cap figures attached to each name are aggregator snapshots (stockanalysis.com-style sources referenced by named research passes) that may postdate the event by days, flagged per-name where materially borderline.
- VIX close for 07-23 required rejecting one source's figure (16.64) as a same-number-as-prior-day artifact; the adopted range (18.7-19.2) rests on two independent Tier-2 sources rather than one precise settlement print.
- 10-year Treasury yield, WTI and Brent closes for 07-23 are each UNVERIFIED to the dollar/basis-point; reported as ranges rather than false-precision points.
- Multiple move-percentage figures this run carry genuine cross-source conflicts that were NOT resolved by picking a 'most likely' number: STM (-12% to -18.67%), TMUS (-6.61% to -11%), LUV (-6.19% vs -3.84%). Each is flagged with 'magnitude_unreconciled' rather than silently averaged.
- CBOE put/call ratio remains unresolved for a second consecutive run: Convex and CBOE.com's own live snapshot disagree by roughly 2x, and no historical archive was located to reconcile them. No level is quoted anywhere in this artifact.
- No contract-level volume-vs-prior-OI is available on any free source for a historical date - the brief's priority-1 options signal was not computable for any name this run either.
- CMCSA's earnings-day direction could not be established at all (directly conflicting Tier-2 headlines); rather than force a rising/falling assignment, the name was excluded entirely.
- SPCX's basic public-listing status is contested across the free sources consulted this run - flagged as a standing data-quality issue rather than resolved.
- TRACK B THIS RUN IS INTENTIONALLY MOSTLY UNCHANGED FROM 07-22. This is not a research shortcut: the project's own instructions state Track B should be stable and that large day-to-day churn is a red flag. Two names (GOOGL, TSLA) had catalysts that were explicitly anticipated in the prior write-up materialize this window, and those two entries were updated with the realized outcome and a small, explained sub-score adjustment; the other 18 names carry forward unchanged.
- Sentiment trackers (AltIndex, ApeWisdom) have no historical mode on free tiers; snapshots used are dated 07-24/07-26 and in-window peaks are inferred from large negative 24h mention deltas, not directly measured.
Not financial advice. Educational/analytical only — generated by Daily Market Pulse template v1 - backdated run for 2026-07-23, compiled 2026-07-26 via four fresh research desks (market regime, Track A movers, options+sentiment, catalyst calendar) plus a carried-forward, selectively-updated Track B. Do your own diligence.